Re: Intense Androgen-Deprivation Therapy with Abiraterone Acetate plus Leuprolide Acetate in Patients with Localized High-Risk
ثبت نشده
چکیده
منابع مشابه
Re: Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study.
PURPOSE Cure rates for localized high-risk prostate cancers (PCa) and some intermediate-risk PCa are frequently suboptimal with local therapy. Outcomes are improved by concomitant androgen-deprivation therapy (ADT) with radiation therapy, but not by concomitant ADT with surgery. Luteinizing hormone-releasing hormone agonist (LHRHa; leuprolide acetate) does not reduce serum androgens as effectiv...
متن کاملRe: Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.
BACKGROUND Abiraterone acetate, a drug that blocks endogenous androgen synthesis, plus prednisone is indicated for metastatic castration-resistant prostate cancer. We evaluated the clinical benefit of abiraterone acetate plus prednisone with androgen-deprivation therapy in patients with newly diagnosed, metastatic, castration-sensitive prostate cancer. METHODS In this double-blind, placebo-co...
متن کاملLATITUDE: A Phase III, Double-Blind, Randomized Trial of Androgen Deprivation Therapy with Abiraterone Acetate Plus Predni- sone or Placebos in Newly Diagnosed High-Risk Metastatic Hormone-Naive Prostate Cancer
Dr. Fizazi and colleagues presented their much anticipated results from the LATITUDE trial at the 2017 American Society of Clinical Oncology (ASCO) annual meeting. LATITUDE is a phase III, double-blind, randomized study that tested androgen deprivation therapy (ADT) with abiraterone acetate (AA) plus prednisone (P) vs. ADT + placebo in men newly diagnosed with highrisk metastatic hormone-naïve ...
متن کاملUnusual side effect from a luteinizing hormone-releasing hormone agonist, leuprorelin, in the treatment of prostate cancer: a case report
BACKGROUND The treatment options for high-risk prostate cancer are either radical prostatectomy or radiotherapy/brachytherapy depending on the patients' prognosis. In older men with multiple comorbidities, radiotherapy with androgen deprivation therapy is an attractive option. Common side effects of androgen deprivation therapy include hot flushes, tiredness, increased risk of fractures, increa...
متن کامل[Management of patients with castration-resistant metastatic prostate cancer].
Prostate cancer belongs to the most common malignant tumors in males. Almost in all patients in advanced stage, disease progression occurs despite of castration therapy. Initial treatment of metastatic disease is androgen deprivation therapy. In the case of castration-resistant disease development in asymptomatic patients, it is a combination of abiraterone acetate plus prednisone and in sympto...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2015